Nov 22, 2011 | RxPG News
Derivative of the agent zileuton has proteasome inhibiting properties
New medication could be developed on the basis of this previously unknown binding mechanism.
Singulair , Accolate , Zyflo and Zyflo CR have modified their product labeling to include information about certain potential mental health side effects that have been noted in patients using these products.
Also on Topix